Drugs / TRX103
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07427628 | Mar 2026 → Dec 2028 expected | uveitis | Quan Dong Nguyen | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06462365 | Apr 2024 → Apr 2026 overdue | B-cell adult acute lymphocytic leukemia, T-cell adult acute lymphocytic leukemia, acute graft versus host disease, acute myeloid leukemia +3 | Tr1X, Inc. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06721962 | May 2025 → Jan 2026 overdue | Crohn disease | Tr1X, Inc. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRX-103 | “The purpose of this Phase 1, first in uveitis open-label study is to assess the safety and tolerability of TRX-103 in patients with non infectious uveitis (NIU).” NCT07427628 ↗ |